Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Tóm tắt
Cancer is associated with higher morbidity and mortality and is the second leading cause of death in the US. Further, in some nations, cancer has overtaken heart disease as the leading cause of mortality. Identification of molecular mechanisms by which cancerous cells evade T cell-mediated cytotoxic damage has led to the modern era of immunotherapy in cancer treatment. Agents that release these immune brakes have shown activity to recover dysfunctional T cells and regress various cancer. Both cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and Programmed Death-1 (PD-1) play their role as physiologic brakes on unrestrained cytotoxic T effector function. CTLA-4 (CD 152) is a B7/CD28 family; it mediates immunosuppression by indirectly diminishing signaling through the co-stimulatory receptor CD28. Ipilimumab is the first and only FDA-approved CTLA-4 inhibitor; PD-1 is an inhibitory transmembrane protein expressed on T cells, B cells, Natural Killer cells (NKs), and Myeloid-Derived Suppressor Cells (MDSCs). Programmed Death-Ligand 1 (PD-L1) is expressed on the surface of multiple tissue types, including many tumor cells and hematopoietic cells. PD-L2 is more restricted to hematopoietic cells. Blockade of the PD-1 /PDL-1 pathway can enhance anti-tumor T cell reactivity and promotes immune control over the cancerous cells. Since the FDA approval of ipilimumab (human IgG1 k anti-CTLA-4 monoclonal antibody) in 2011, six more immune checkpoint inhibitors (ICIs) have been approved for cancer therapy. PD-1 inhibitors nivolumab, pembrolizumab, cemiplimab and PD-L1 inhibitors atezolizumab, avelumab, and durvalumab are in the current list of the approved agents in addition to ipilimumab. In this review paper, we discuss the role of each immune checkpoint inhibitor (ICI), the landmark trials which led to their FDA approval, and the strength of the evidence per National Comprehensive Cancer Network (NCCN), which is broadly utilized by medical oncologists and hematologists in their daily practice.
Từ khóa
Tài liệu tham khảo
Murphy, S.L., Xu, J., Kochanek, K.D., and Arias, E. (2018). Mortality in the United States, 2017. Nchs Data Brief, 1–8.
Weir, 2016, Heart Disease and Cancer Deaths-Trends and Projections in the United States, 1969–2020, Prev. Chronic Dis., 13, E157, 10.5888/pcd13.160211
French, 2012, Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer, J. Clin. Endocrinol. Metab., 97, E934, 10.1210/jc.2011-3428
Severson, 2015, PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer, Cancer Immunol. Res., 3, 620, 10.1158/2326-6066.CIR-14-0201
McCarthy, 2006, The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas, Iowa Orthop. J., 26, 154
Fyfe, 1995, Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy, J. Clin. Oncol., 13, 688, 10.1200/JCO.1995.13.3.688
Klapper, 2008, High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: A retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006, Cancer, 113, 293, 10.1002/cncr.23552
Glickman, 2014, The mechanism of action of BCG therapy for bladder cancer--a current perspective, Nat. Rev. Urol., 11, 153, 10.1038/nrurol.2014.15
Advani, 2018, CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma, N. Engl. J. Med., 379, 1711, 10.1056/NEJMoa1807315
Anderson, 2007, Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells, Science, 318, 1141, 10.1126/science.1148536
Fourcade, 2012, CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1, Cancer Res., 72, 887, 10.1158/0008-5472.CAN-11-2637
Gough, 2010, Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice, J. Immunother., 33, 798, 10.1097/CJI.0b013e3181ee7095
Li, 2011, Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function, J. Immunother., 34, 236, 10.1097/CJI.0b013e318209e7ec
Lines, 2014, VISTA is an immune checkpoint molecule for human T cells, Cancer Res., 74, 1924, 10.1158/0008-5472.CAN-13-1504
Ngiow, 2011, Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors, Cancer Res., 71, 3540, 10.1158/0008-5472.CAN-11-0096
Schaer, 2010, Anti-GITR antibodies--potential clinical applications for tumor immunotherapy, Curr. Opin. Investig. Drugs, 11, 1378
Wang, 2011, VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses, J. Exp. Med., 208, 577, 10.1084/jem.20100619
Watanabe, 2003, BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1, Nat. Immunol., 4, 670, 10.1038/ni944
Woo, 2012, Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape, Cancer Res., 72, 917, 10.1158/0008-5472.CAN-11-1620
Chen, 2013, Molecular mechanisms of T cell co-stimulation and co-inhibition, Nat. Rev. Immunol., 13, 227, 10.1038/nri3405
Greenwald, 2001, CTLA-4 Regulates Induction of Anergy In Vivo, Immunity, 14, 145, 10.1016/S1074-7613(01)00097-8
Walker, 2011, The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses, Nat. Rev. Immunol., 11, 852, 10.1038/nri3108
Qureshi, 2011, Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4, Science, 332, 600, 10.1126/science.1202947
Schadendorf, 2015, Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma, J. Clin. Oncol., 33, 1889, 10.1200/JCO.2014.56.2736
Amarnath, 2011, The PDL1-PD1 axis converts human TH1 cells into regulatory T cells, Sci. Transl. Med., 3, 111ra120, 10.1126/scitranslmed.3003130
Francisco, 2009, PD-L1 regulates the development, maintenance, and function of induced regulatory T cells, J. Exp. Med., 206, 3015, 10.1084/jem.20090847
McDermott, 2013, Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20), Ann. Oncol., 24, 2694, 10.1093/annonc/mdt291
Postow, 2015, Nivolumab and ipilimumab versus ipilimumab in untreated melanoma, N. Engl. J. Med., 372, 2006, 10.1056/NEJMoa1414428
Larkin, 2015, Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, N. Engl. J. Med., 373, 23, 10.1056/NEJMoa1504030
Eggermont, 2016, Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy, N. Engl. J. Med., 375, 1845, 10.1056/NEJMoa1611299
Hammers, 2017, Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study, J. Clin. Oncol., 35, 3851, 10.1200/JCO.2016.72.1985
Motzer, 2015, Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, N. Engl. J. Med., 373, 1803, 10.1056/NEJMoa1510665
Overman, 2017, Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study, Lancet Oncol., 18, 1182, 10.1016/S1470-2045(17)30422-9
Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N. Engl. J. Med., 363, 711, 10.1056/NEJMoa1003466
Weber, 2015, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial, Lancet Oncol., 16, 375, 10.1016/S1470-2045(15)70076-8
Brahmer, 2015, Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N. Engl. J. Med., 373, 123, 10.1056/NEJMoa1504627
Borghaei, 2015, Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer, N. Engl. J. Med., 373, 1627, 10.1056/NEJMoa1507643
Antonia, 2016, Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial, Lancet Oncol., 17, 883, 10.1016/S1470-2045(16)30098-5
Motzer, 2018, Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma, N. Engl. J. Med., 378, 1277, 10.1056/NEJMoa1712126
Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma, N. Engl. J. Med., 372, 311, 10.1056/NEJMoa1411087
Ferris, 2016, Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck, N. Engl. J. Med., 375, 1856, 10.1056/NEJMoa1602252
Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., Plimack, E.R., Vaena, D., Grimm, M.O., and Bracarda, S. (2017). Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. Lancet Oncol.
Overman, 2018, Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer, J. Clin. Oncol., 36, 773, 10.1200/JCO.2017.76.9901
Sangro, 2017, Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial, Lancet, 389, 2492, 10.1016/S0140-6736(17)31046-2
Robert, 2014, Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial, Lancet, 384, 1109, 10.1016/S0140-6736(14)60958-2
Robert, 2015, Pembrolizumab versus Ipilimumab in Advanced Melanoma, N. Engl. J. Med., 372, 2521, 10.1056/NEJMoa1503093
Ribas, 2015, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial, Lancet Oncol., 16, 908, 10.1016/S1470-2045(15)00083-2
Wan, 2020, Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC, Cancer Med., 9, 1683, 10.1002/cam4.2793
Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial, Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7
Reck, M., Rodriguez-Abreu, D., Robinson, A.G., Hui, R., Csoszi, T., Fulop, A., Gottfried, M., Peled, N., Tafreshi, A., and Cuffe, S. (2016). Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med.
Langer, 2016, Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: A randomised, phase 2 cohort of the open-label KEYNOTE-021 study, Lancet Oncol., 17, 1497, 10.1016/S1470-2045(16)30498-3
Gandhi, 2018, Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N. Engl. J. Med., 378, 2078, 10.1056/NEJMoa1801005
Luft, 2018, Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer, N. Engl. J. Med., 379, 2040, 10.1056/NEJMoa1810865
Luft, 2018, Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC), J. Clin. Oncol., 36, 105, 10.1200/JCO.2018.36.15_suppl.105
Mok, 2019, Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial, Lancet, 393, 1819, 10.1016/S0140-6736(18)32409-7
Seiwert, 2016, Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial, Lancet Oncol., 17, 956, 10.1016/S1470-2045(16)30066-3
Rischin, 2019, Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), J. Clin. Oncol., 37, 6000, 10.1200/JCO.2019.37.15_suppl.6000
Chen, 2017, Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma, J. Clin. Oncol., 35, 2125, 10.1200/JCO.2016.72.1316
Bellmunt, 2017, Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma, N. Engl. J. Med., 376, 1015, 10.1056/NEJMoa1613683
Balar, 2017, First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study, Lancet Oncol., 18, 1483, 10.1016/S1470-2045(17)30616-2
Boyiadzis, 2018, Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease, J. Immunother. Cancer, 6, 35, 10.1186/s40425-018-0342-x
Diaz, L., Marabelle, A., Kim, T.W., Geva, R., Van Cutsem, E., André, T., Ascierto, P., Maio, M., Delord, J.P., and Gottfried, M. (2017). 386PEfficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers. Ann. Oncol., 28.
Fuchs, 2018, Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 TrialPembrolizumab in Advanced Gastric and Gastroesophageal Junction CancerPembrolizumab in Advanced Gastric and Gastroesophageal Junction Cancer, JAMA Oncol., 4, e180013, 10.1001/jamaoncol.2018.0013
Le, 2015, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, N. Engl. J. Med., 372, 2509, 10.1056/NEJMoa1500596
Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733
Kojima, 2019, Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study, J. Clin. Oncol., 37, 2, 10.1200/JCO.2019.37.4_suppl.2
Chung, 2019, Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study, J. Clin. Oncol., 37, 1470, 10.1200/JCO.18.01265
Zinzani, 2017, Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): Interim analysis of the KEYNOTE-170 phase 2 trial, Hematol. Oncol., 35, 62, 10.1002/hon.2437_49
Zhu, 2018, Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial, Lancet Oncol., 19, 940, 10.1016/S1470-2045(18)30351-6
Nghiem, 2019, Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy, J. Clin. Oncol., 37, 693, 10.1200/JCO.18.01896
Rini, 2019, Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N. Engl. J. Med., 380, 1116, 10.1056/NEJMoa1816714
Migden, 2018, PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma, N. Engl. J. Med., 379, 341, 10.1056/NEJMoa1805131
Kaufman, 2016, Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial, Lancet Oncol., 17, 1374, 10.1016/S1470-2045(16)30364-3
Keilholz, 2019, Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial, J. Immunother. Cancer, 7, 12, 10.1186/s40425-018-0459-y
Motzer, 2019, Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N. Engl. J. Med., 380, 1103, 10.1056/NEJMoa1816047
Massard, 2016, Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer, J. Clin. Oncol., 34, 3119, 10.1200/JCO.2016.67.9761
Antonia, 2018, Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC, N. Engl. J. Med., 379, 2342, 10.1056/NEJMoa1809697
Necchi, 2017, Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: Post-progression outcomes from the phase II IMvigor210 study, Ann. Oncol., 28, 3044, 10.1093/annonc/mdx518
Bordoni, 2019, Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study, Eur. J. Cancer, 107, 124, 10.1016/j.ejca.2018.11.020
Fehrenbacher, 2016, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial, Lancet, 387, 1837, 10.1016/S0140-6736(16)00587-0
Reck, 2019, Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial, Lancet Respir. Med., 7, 387, 10.1016/S2213-2600(19)30084-0
Horn, 2018, First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer, N. Engl. J. Med., 379, 2220, 10.1056/NEJMoa1809064